20/20 Biolabs, Inc. AIDX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.04M | 1.84M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.04M | 1.84M | -- | -- | -- |
| Cost of Revenue | 1.40M | 1.34M | -- | -- | -- |
| Gross Profit | 643.10K | 501.70K | -- | -- | -- |
| SG&A Expenses | 4.37M | 3.89M | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.44M | 5.85M | -- | -- | -- |
| Operating Income | -4.40M | -4.00M | -- | -- | -- |
| Income Before Tax | -5.81M | -5.15M | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.81 | -5.15 | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.81M | -5.15M | -- | -- | -- |
| EBIT | -4.40M | -4.00M | -- | -- | -- |
| EBITDA | -4.32M | -3.92M | -- | -- | -- |
| EPS Basic | -0.95 | -0.87 | -- | -- | -- |
| Normalized Basic EPS | -0.53 | -0.55 | -- | -- | -- |
| EPS Diluted | -0.96 | -0.87 | -- | -- | -- |
| Normalized Diluted EPS | -0.53 | -0.55 | -- | -- | -- |
| Average Basic Shares Outstanding | 28.52M | 22.56M | -- | -- | -- |
| Average Diluted Shares Outstanding | 28.52M | 22.56M | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |